EnzySurge has developed a device for the continuous irrigation of chronic wounds.
Israeli start-up EnzySurge Ltd., which has develops treatments for chronic wounds, has closed its third financing round, raising $1.7 million from private investors at a value of $7 million. The round was managed by accountant Eli Gilboa of Gilboa & Licht Investment House, one of EnzySurge’s existing investors. The company has raised $2 million to date.
EnzySurge recently received US Food and Drug Administration (FDA) approval to market a product named DermaStream, which is a device for continuous irrigation of chronic wounds such as venous ulcers and diabetic foot sores. The company has also recently completed the development of a new solution-based treatment called EnzyStream for irrigating chronic wounds. The product is currently awaiting approval from the FDA. EnzySurge is due to conduct multi-location safety and efficacy trials for both its products.
The market for treatments for chronic wounds is one of the larger and more developed in the medical field. Companies in Israel and abroad are developing a range of solutions for wound treatment from drugs to sophisticated medical devices, although at present no solution exists that guarantees healing. Most applications work by disinfecting and debriding the wound in order to encourage a process of natural healing as far as possible.
Published by Globes [online], Israel business news - www.globes.co.il - on December 31, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006